Sugi Predict

Sugi Predict / Compounds / SCHEMBL1490855

SCHEMBL1490855

SCHEMBL1490855

CC(C)(O)CNc1c([N+](=O)[O-])cnc2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29481131 1.00 SMN1; SMN2 (0.41) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL14345152 0.90 MEN1 (0.43) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL4313344 0.89 MAPT (0.40) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL30361640 0.89 MAPT (0.40) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL29271216 0.88 CHRM2 (0.43) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL1043132 0.88 MEN1 (0.41) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL5794757 0.88 MEN1 (0.41) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL201873 0.85 MAPT (0.40) SMN1; SMN2MAPTMEN1KMT2AMAPK1
SCHEMBL3867800 0.84 EGLN2 (0.39) MAPTALDH1A1HPGDPDCD1CD274
SCHEMBL3861961 0.84 TNF (0.39) PDCD1CD274ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683669-A2 COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT Purdue Research Foundation (US) 2026-01-28 — — EP disclosed
US-20250352652-A1 COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER PURDUE RESEARCH FOUNDATION 2025-11-20 — — US disclosed
US-20250269036-A1 METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT PURDUE RESEARCH FOUNDATION 2025-08-28 — — US disclosed
US-12397059-B2 Compounds and methods for the treatment and prevention of fibrotic disease states and cancer PURDUE RESEARCH FOUNDATION (US) 2025-08-26 — — US disclosed
WO-2024197318-A2 COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT PURDUE RESEARCH FOUNDATION (US) 2024-09-26 — — WO disclosed
CN-117858706-A Methods of enhancing engineered cell therapies in cancer treatment 普渡研究基金会 2024-04-09 — — CN disclosed
US-20230355750-A1 KINETICALLY ACTING ADJUVANT ENSEMBLE Progeneer Inc. (KR) 2023-11-09 — — US disclosed
US-20230355750-A1 KINETICALLY ACTING ADJUVANT ENSEMBLE Progeneer Inc. (KR) 2023-11-09 — — US disclosed
US-20230355750-A1 KINETICALLY ACTING ADJUVANT ENSEMBLE Progeneer Inc. (KR) 2023-11-09 — — US disclosed
EP-4271378-A1 METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT Purdue Research Foundation (US) 2023-11-08 — — EP disclosed
WO-2005076783-A2 SULFONE SUBSTITUTED IMIDAZO RING ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-08-25 — — WO disclosed
WO-2005048945-A2 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 — — WO disclosed
WO-2005048933-A2 OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-02 — — WO disclosed
EP-0389302-B1 Olefinic 1H-imidazo [4,5-c]quinolin-4-amines RIKER LABORATORIES INC (US) 1994-08-31 — — EP disclosed
US-5037986-A Olefinic 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-08-06 — — US disclosed
EP-0389302-A1 Olefinic 1H-imidazo [4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1990-09-26 — — EP disclosed
EP-0385630-A2 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals RIKER LABORATORIES, INC. (US) 1990-09-05 — — EP disclosed
US-4929624-A Olefinic 1H-imidazo(4,5-c)quinolin-4-amines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-05-29 — — US disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 — — US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12397059-B2 Compounds and methods for the treatment and prevention of fibrotic disease states and cancer MSR1, MIF, MMP12 SMN1; SMN2 2885/4885MAPT 3565/4885MEN1 1888/4885
US-20230355750-A1 KINETICALLY ACTING ADJUVANT ENSEMBLE GPX1, GSS, IFNG SMN1; SMN2 4454/4885MAPT 3697/4885MEN1 4003/4885
US-20250269036-A1 METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT CD47, FOLR1, CD14 SMN1; SMN2 2557/4885MAPT 1997/4885MEN1 798/4885
US-20250352652-A1 COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER MSR1, MIF, MMP12 SMN1; SMN2 2885/4885MAPT 3565/4885MEN1 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.